Statera Biopharma Stock Net Asset
Statera Biopharma fundamentals help investors to digest information that contributes to Statera Biopharma's financial success or failures. It also enables traders to predict the movement of Statera Pink Sheet. The fundamental analysis module provides a way to measure Statera Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Statera Biopharma pink sheet.
Statera |
Statera Biopharma Company Net Asset Analysis
Statera Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Statera Biopharma Net Asset | 21.17 M |
Most of Statera Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Statera Biopharma has a Net Asset of 21.17 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
Statera Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.Statera Biopharma is currently under evaluation in net asset category among its peers.
Statera Fundamentals
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Shares Owned By Insiders | 15.93 % | ||||
| Shares Owned By Institutions | 5.41 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 1.49 M | ||||
| Gross Profit | 998.72 K | ||||
| EBITDA | (97.27 M) | ||||
| Net Income | (101.88 M) | ||||
| Cash And Equivalents | 506.1 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 10.62 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (28.19 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Number Of Employees | 46 | ||||
| Market Capitalization | 1.97 M | ||||
| Total Asset | 21.17 M | ||||
| Z Score | -13.2 | ||||
| Net Asset | 21.17 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |